TY - JOUR T1 - Assessing the risk of COVID-19 importation and the effect of quarantine JF - medRxiv DO - 10.1101/2020.08.12.20173658 SP - 2020.08.12.20173658 AU - Julien Arino AU - Nicolas Bajeux AU - Stéphanie Portet AU - James Watmough Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/14/2020.08.12.20173658.abstract N2 - Objectives During the early stage of COVID-19 spread, many governments and regional jurisdictions put in place travel restrictions and imposed quarantine after arrivals in an effort to slow down or stop the importation of cases. At the same time, they implemented non-pharmaceutical interventions (NPI) to curtail local spread. We assess the risk of importation of COVID-19 in locations that are at that point without infection or where local chains of transmission have extinguished, and evaluate the role of quarantine in this risk.Methods A stochastic SLIAR epidemic model is used. The effect of the rate, size, and nature of importations is studied and compared to that of NPI on the risk of importation-induced local transmission chains. The effect of quarantine on the rate of importations is assessed, as well as its efficacy as a function of its duration.Results The rate of importations plays a critical role in determining the risk that case importations lead to local transmission chains, more so than local transmission characteristics, i.e., strength of NPI. The latter influences the severity of the outbreaks. Quarantine after arrival in a location is an efficacious way to reduce the rate of importations.Conclusions Locations that see no or low level local transmission should ensure that the rate of importations remains low. A high level of compliance with post-arrival quarantine followed by testing achieves this objective with less of an impact than travel restrictions or bans.Competing Interest StatementThe authors have declared no competing interest.Funding StatementJA, SP and JW are supported in part by NSERC Discovery Grants. JA and JW are supported in part by CIHR. JA was supported in part by the Public Health Agency of Canada. JW is supported in part by the New Brunswick Health Research Fund. The sponsors played no role in the design of the study nor in the decision to submit this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable: this mathematical research work only involves data publicly available online.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesR code will be added to the Github repository. https://github.com/julien-arino/covid-19-importation-risk ER -